A Neuroimmunological Perspective on Endometriosis Symptoms

A Neuroimmunological Perspective on Endometriosis Symptoms

Introduction

Endometriosis is a chronic gynecological disorder characterized by endometrial-like tissue growing outside the uterus, often leading to pain (dysmenorrhea, pelvic pain, dyspareunia) and infertility. Traditionally, endometriosis has been viewed primarily as a hormone-driven disease, given its estrogen dependence. However, many patients continue to suffer from severe symptoms despite hormonal therapies, suggesting that non-hormonal mechanisms play a significant role in driving endometriosis-associated pain and lesion progression. Recent insights point to a complex interplay between the nervous and immune systems—a neuroimmunological axis—in the pathophysiology of endometriosis. In particular, emerging evidence implicates neuropeptidergic circuits (networks of neurons communicating via neuropeptides) and immune mediators in generating and perpetuating the chronic inflammation, pain, and tissue changes seen in endometriosis. This neuroimmune perspective offers a more comprehensive theory of endometriosis symptoms and opens the door to novel non-hormonal therapeutic strategies.

Neuropeptidergic Circuits in Endometriosis

Endometriotic lesions are highly innervated by nerve fibers, including sensory (nociceptive) nerves that release neuropeptides. Neuropeptidergic circuits refer to pathways in which neurons signal via neuropeptides (small protein-like neurotransmitters) to influence target cells. In endometriosis, two key neuropeptides are Substance P (SP) and Calcitonin Gene-Related Peptide (CGRP), which are released from peptidergic sensory nerves within and around lesions. These neuropeptides not only transmit pain signals but also exert powerful effects on surrounding tissues. For example, SP acting on its receptor (neurokinin-1 receptor, NK1R) and CGRP acting on its receptor complex can induce cellular changes in endometriotic lesions that promote lesion growth and fibrosis.

A 2019 study demonstrated that SP and CGRP trigger processes like epithelial-mesenchymal transition (EMT) and fibroblast-to-myofibroblast transformation in endometriotic cells, ultimately increasing collagen deposition and fibrous tissue formation in lesions. Notably, blocking the NK1R or CGRP receptors in these models prevented those fibrotic changes, highlighting that these neuropeptide signals are driving lesion progression. Deep infiltrating endometriosis lesions, which tend to be very painful and fibrotic, have been found to contain higher densities of nerve fibers and elevated levels of NK1R and CGRP receptor components, correlating with greater fibrosis. This indicates that hyper-innervation and neuropeptide signaling contribute directly to the aggressive nature of such lesions.

Beyond fibrogenesis, neuropeptides like SP and CGRP are central to pain generation and neurogenic inflammation in endometriosis. When released from sensory nerve endings, SP and CGRP cause vasodilation of blood vessels and increased vascular permeability, leading to plasma extravasation (swelling) in the lesion microenvironment. SP, in particular, can bind NK1 receptors on nearby immune and endothelial cells, stimulating the release of inflammatory mediators like nitric oxide and histamine. CGRP similarly promotes vasodilation and can contribute to inflammation. These effects, collectively termed neurogenic inflammation, mean that the nerves in lesions are not just passive conveyors of pain but active instigators of an inflammatory response via their neuropeptides. In essence, the sensory nerve fibers form a neuropeptidergic circuit that amplifies local inflammation and pain: as the lesion’s nerves fire and release SP/CGRP, they exacerbate tissue injury and inflammation, which can then further stimulate nerve activity—a vicious cycle.

Neuro-Immune Interactions and the Neuroimmunology of Endometriosis

A hallmark of endometriosis lesions is a chronically inflamed microenvironment rich in immune cells (such as macrophages, mast cells, and T cells) and cytokines. Neuroimmunology is the field that examines crosstalk between the nervous and immune systems. In endometriosis, this crosstalk is pivotal in driving symptoms. The inflamed lesions essentially become an intersection where nerve fibers and immune cells continuously interact, perpetuating each other’s activation in a positive feedback loop.

One key player in this loop is the mast cell, an immune cell known for releasing histamine and other inflammatory mediators. Mast cells are found in elevated numbers in endometriosis lesions, often in close proximity to nerve fibers. Chronic stimulation of sensory nerves leads to the release of neuropeptides like Substance P, which can directly activate mast cells via NK1 receptors on these cells. Upon activation (degranulation), mast cells release a host of pro-inflammatory substances—histamine, prostaglandins, tryptase, nerve growth factor (NGF), tumor necrosis factor (TNF), interleukins, etc.—into the local tissue. Histamine and prostaglandins sensitize nearby nerve endings, lowering their threshold for firing and thereby increasing pain signals. NGF released by mast cells (and macrophages) encourages the growth of new nerve fibers into the lesion and further sensitizes existing nerves to pain. Thus, mast cells amplify pain and inflammation in lesions. In turn, the activated sensory nerves (now sprouted and sensitized by NGF and histamine) release more neuropeptides. This creates a self-perpetuating neuroimmune feedback loop: sensory nerves stimulate mast cells, and mast cells stimulate sensory nerves, each escalation worsening pain and inflammation. This loop is a prime example of neuroimmunology in endometriosis—the nervous and immune systems acting as co-conspirators in disease pathology.

Macrophages, another abundant immune cell in endometriosis, also engage in intimate cross-talk with nerves. Lesion-associated macrophages often adopt a pro-inflammatory and pro-growth phenotype, secreting cytokines (like IL-1β, IL-6, IL-8, TNF-α) as well as growth factors such as NGF and VEGF (vascular endothelial growth factor). Under the influence of estrogen (which is elevated in lesions due to local aromatase activity), macrophages become especially activated and may polarize toward a nerve-interacting state. Estrogen can even act directly on neurons and immune cells to modulate this interaction. Research has shown that estrogen promotes nerves to secrete certain chemokines that attract macrophages into lesions. Those recruited macrophages, in an estrogen-rich setting, produce more NGF and inflammatory cytokines, which then act on peripheral nerve fibers. Persistent stimulation of nociceptor (pain) neurons by macrophage-derived cytokines leads the nerves to release more “inflammatory neurotransmitters” (i.e., neuropeptides and glutamate), further fueling neuroinflammation. This estrogen-regulated neuro-immune circuit effectively sensitizes peripheral nerves and contributes to what can be described as neuropathic pain in endometriosis. It explains why endometriosis pain often has features of nerve pain (burning, shooting) and can become chronic and disproportionate to lesion size. In deep infiltrating endometriosis, for instance, studies have noted a high density of nerve fibers intertwined with activated immune cells, reinforcing the idea that the severity of pain is linked to this local neuroimmune dysregulation.

In summary, the neuroimmunology of endometriosis involves a multifaceted loop: sensory nerves, through neuropeptides (SP, CGRP, etc.), trigger immune cells (mast cells, macrophages); those immune cells, in turn, release mediators (histamine, cytokines, NGF) that activate and even sprout more nerve fibers. Estrogen augments this loop by making both the nerves and immune cells more reactive. The outcome is chronic inflammation, pain generation, and lesion progression beyond what estrogen alone would cause. Over time, repeated stimulation can lead to central sensitization as well—changes in the spinal cord and brain pain pathways that maintain pain perception even with minimal peripheral input. Thus, endometriosis pain is not purely inflammatory or purely hormonal—it is neurogenic inflammation on a background of endocrine and immune dysfunction. Understanding these neuropeptidergic and immune circuits gives us new insight into why endometriosis can be so painful and persistent, and why some patients experience systemic symptoms (fatigue, central pain amplification, comorbid syndromes) involving the nervous and immune systems.

Implications for Treatment: Targeting Neuroimmune Pathways

Viewing endometriosis through a neuroimmune lens suggests that effective management may require targeting the nervous system and immune system interactions, in addition to traditional hormonal suppression. Many patients cannot tolerate hormonal therapy or wish to avoid it (for example, those trying to conceive or those with contraindications), so developing non-hormonal treatments is a priority. Below are several potential non-hormonal therapeutic approaches that emerge from the neuroimmunology theory, and these could be used in combination to address different aspects of the disease:

• Neurokinin-1 (NK1) Receptor Antagonists: Blocking the receptor for Substance P can theoretically dampen both pain transmission and neurogenic inflammation. Aprepitant is a well-known NK1 receptor antagonist (used clinically as an anti-nausea drug). NK1 antagonists have demonstrated broad anti-inflammatory and analgesic effects in other conditions. By preventing SP from binding to NK1R on neurons and immune cells, aprepitant or similar agents could reduce pain signaling and mast cell activation in lesions. While not yet standard therapy for endometriosis, the rationale is strong: given the evidence that SP/NK1 drives lesion fibrosis and pain, an NK1 antagonist might relieve symptoms and possibly slow lesion progression. In practice, one could envision combining aprepitant with other medications to break the pain-inflammatory cycle. Early-stage investigations or case reports may be needed to confirm its efficacy in endometriosis-associated pain, but this represents a promising repurposing of a neuropeptide-targeted drug.
• CGRP Pathway Inhibitors: CGRP is another neuropeptide heavily involved in pain and vasodilation (for instance, it’s a key mediator in migraine headaches). New CGRP inhibitors (both monoclonal antibodies and small molecule antagonists) are now available for migraine treatment. If CGRP is contributing to endometriosis pain and inflammation, these drugs could be repurposed to help endometriosis patients. Blocking CGRP might reduce lesion vascularization and inflammation, potentially alleviating pain. This idea remains speculative but is supported by the mechanistic evidence of CGRP’s role in lesion development. It’s an area ripe for research, given the safety profile of CGRP inhibitors in migraine use.
• Mast Cell Stabilizers and Antihistamines: Since mast cells orchestrate a lot of the inflammation and nerve activation in lesions, therapies that calm mast cells could break the vicious cycle. Mast cell stabilizer medications (such as cromolyn or ketotifen) could reduce mast cell degranulation, thereby limiting the release of histamine, prostaglandins, and NGF in lesions. Likewise, antihistamines (H1 and H2 blockers) might counteract the effects of mast cell mediators and reduce nerve irritation. Some clinicians have empirically tried antihistamine regimens for patients with co-occurring mast cell activation issues and endometriosis, noting improvements in pain and allergy-like symptoms. Though formal trials are lacking, the mast cell–nerve feedback loop provides a clear rationale: by inhibiting mast cell activity, we may reduce neurogenic inflammation and pain signaling in endometriosis lesions.
• Neuropathic Pain Modulators: Drugs that are used for neuropathic pain can be valuable in endometriosis by dampening nerve excitability and central sensitization. Examples include gabapentin and pregabalin (calcium channel modulators), and SNRIs/tricyclic antidepressants (such as duloxetine or amitriptyline, which enhance inhibitory neurotransmitters). These medications do not target inflammation directly, but they reduce the firing of overactive pain pathways. Gabapentin, for instance, has shown efficacy in some women with chronic pelvic pain and is being used more frequently in endometriosis-associated pain management. By combining a neuromodulator like gabapentin with an anti-inflammatory approach, one can address both the “nerve” and “immune” sides of the equation.
• Anti-Inflammatory and Immunomodulatory Therapies: Given the plethora of cytokines and immune cells involved in endometriosis, various immunomodulators have been investigated. Broad anti-inflammatories like nonsteroidal anti-inflammatory drugs (NSAIDs) are already a mainstay for symptomatic relief (targeting prostaglandins to reduce menstrual pain). Beyond that, specific cytokine inhibitors have been tried: anti–TNF-α drugs (like infliximab or etanercept) were tested in endometriosis due to high TNF levels in lesions, but results were disappointing (no significant pain improvement in trials). Other immune targets such as IL-6 or IL-1 are theoretically interesting, though not yet clinically tested for endometriosis. A more targeted experimental therapy is JNK inhibitors—these block an inflammatory signaling pathway in cells. Bentamapimod (a JNK inhibitor) showed promising results in a small randomized trial, suggesting it reduced endometriosis lesion size and pain, and it is being considered as an adjuvant therapy. Similarly, drugs that inhibit angiogenesis (formation of new blood vessels), like dopamine agonists (e.g., cabergoline), have had some success. Cabergoline can reduce vascular endothelial growth factor, and a trial demonstrated it helped shrink ovarian endometrioma lesions and ease pain, making it a potential non-hormonal option. A 2022 review of non-hormonal treatments concluded that dopamine agonists and bentamapimod are two of the most promising emerging options for endometriosis pain management, whereas anti-TNF biologics and statins have not shown benefit.
• Endocannabinoid System Modulators: The endocannabinoid system (ECS) helps regulate pain and immune responses, and some studies suggest endometriosis may be associated with dysregulation of the ECS (for example, altered levels of cannabinoids or cannabinoid receptors in lesions). Modulating the ECS—either with phytocannabinoids (e.g., cannabidiol, THC) or synthetic agents—may provide analgesic and anti-inflammatory benefits. While clinical data are limited, this is an area of growing patient interest and research.

Functional Connections: Nav1.7 (Suzetrigine) and NK1 (Aprepitant) Pathways

A particularly intriguing therapeutic intersection involves the Nav1.7 sodium channel (the target of suzetrigine) and the neurokinin-1 (NK1) receptor (the target of aprepitant). While these agents act on distinct molecular pathways, they converge functionally in the neuroimmune and visceral pain circuits central to endometriosis pathophysiology:

• Suzetrigine is a selective blocker of Nav1.7, a voltage-gated sodium channel essential for pain signal initiation and propagation in nociceptive neurons. By inhibiting Nav1.7, suzetrigine reduces both neuropathic and visceral pain at the level of the dorsal root ganglion and peripheral nerves.
• Aprepitant is an NK1 receptor antagonist that blocks the action of Substance P, a neuropeptide integral to nausea, vomiting, visceral pain, and central sensitization. By inhibiting NK1, aprepitant reduces both central transmission of nausea and the amplification of visceral discomfort.

Potential Interactions and Synergy:

1. Substance P Sensitizes Nav1.7:
   Substance P, via NK1 receptor activation, can sensitize nociceptors and upregulate sodium channels like Nav1.7. Thus, blocking NK1 (with aprepitant) may indirectly reduce Nav1.7 activity, while direct Nav1.7 blockade (with suzetrigine) prevents the propagation of sensitized pain signals.
2. Overlap in Visceral Pain and Nausea Circuits:
   Both drugs modulate afferent signaling from visceral organs (gut, uterus, etc.). Nav1.7 inhibition dampens pain signaling peripherally, while NK1 antagonism reduces central processing of both pain and nausea. This is particularly relevant in endometriosis, where pain and neurovegetative symptoms (such as nausea and gastrointestinal discomfort) frequently co-occur and are mediated by overlapping neuropeptidergic circuits.
3. Central Sensitization:
   In central sensitization syndromes—including endometriosis-associated pain, fibromyalgia, and irritable bowel syndrome—both Substance P and sodium channels contribute to heightened pain states. Combining therapies that block Nav1.7 and NK1R could therefore have additive or even synergistic effects on visceral hypersensitivity and the broader neuroimmune pain network.

This mechanistic overlap underscores the potential value of combination or sequential therapy targeting both the Nav1.7 and NK1 pathways, especially in patients with refractory pain and prominent neurovegetative symptoms.

Expanded Conclusion: Integrating Somatic and Neurovegetative Symptom Management

Reconceptualizing Endometriosis as a Neuroimmunological Disorder

The proposed model positions endometriosis as a neuroimmunometabolic disease where lesion-derived signals interact with systemic neural and immune networks to produce both localized symptoms (pelvic pain, dyspareunia) and systemic neurovegetative manifestations (fatigue, sleep disturbances, gastrointestinal dysmotility). Three key mechanisms unite these phenomena:

1. Peripheral Sensitization via Neuropeptide-Immune Crosstalk
   • Substance P and CGRP create a self-sustaining inflammatory niche through:
     • Direct activation of mast cells and macrophages
     • Induction of fibroblast-to-myofibroblast transition (promoting fibrosis)
     • Vasodilation/plasma extravasation (contributing to visceral swelling)
   • This peripheral drive explains somatic pain localization but also contributes to neurovegetative symptoms via cytokine spread to adjacent autonomic ganglia (e.g., inferior mesenteric plexus involvement in bowel symptoms).
2. Central Sensitization and Glial Priming
   • Chronic nociceptive input from lesions induces:
     • Spinal cord microglial activation (via ATP and fractalkine signaling)
     • Descending facilitatory pathway dominance over inhibitory controls
     • Corticolimbic reorganization (affecting pain perception and stress responses)
   • These central changes manifest as widespread hyperalgesia, pelvic floor myalgia, and autonomic dysregulation—features poorly addressed by hormonal suppression alone.
3. Systemic Neuroendocrine-Immune Axis Dysfunction
   • Persistent lesion activity drives:
     • Hypothalamic-pituitary-adrenal (HPA) axis exhaustion (fatigue, orthostatic intolerance)
     • Vagus nerve-mediated cytokine signaling (nausea, gastric stasis)
     • Mast cell-derived histamine overflow (pruritus, flushing)

Therapeutic Implications Beyond Hormonal Manipulation

A stratified approach targeting specific neuroimmune components could address both symptom domains:

Symptom Cluster	Mechanism Target	Example Therapies
Somatic Pain	Peripheral nociceptors	Nav1.7 inhibitors (suzetrigine)
	Neurogenic inflammation	Aprepitant (NK1 antagonist)
Neurovegetative	Central glial activation	Ibudilast (PDE4/glial modulator)
	Autonomic dysregulation	Low-dose naltrexone
Systemic	Mast cell hyperactivity	Ketotifen + H1/H2 blockade
	HPA axis dysfunction	Phosphodiesterase 10 inhibitors

 

Clinical Translation Challenges

• Diagnostic Biomarkers: Developing PET ligands for NK1R/CGRP receptor density mapping could identify patients likely to respond to neuropeptide-targeted therapies.
• Combination Strategies: Simultaneous peripheral (e.g., suzetrigine, aprepitant) and central (e.g., gabapentin) modulation may be needed to break pain-inflammation cycles.
• Chronotherapy: Aligning treatment timing with circadian neuroimmune fluctuations (e.g., mast cell mediator release peaks at 4 AM) could optimize efficacy.

This paradigm shift from purely hormonal suppression to neuromodulation-immunomodulation synergy addresses the multidimensional nature of endometriosis symptoms. By targeting the shared neuroimmunological substrate of both somatic and neurovegetative manifestations—and leveraging the functional interplay between targets like Nav1.7 and NK1—we move closer to precision management of this complex disorder.

APPENDIX

 

Appendix1 : Glial Inhibitors and Their Clinical Relevance in Endometriosis

Overview

Glial inhibitors are a diverse group of agents that modulate the activity of glial cells (microglia and astrocytes) in the central nervous system. Glial activation is increasingly recognized as a key driver of central sensitization and chronic pain, including in endometriosis-associated pain syndromes. These agents fall into three broad categories:

1. Direct Glial Modulators / Inhibitors

Agent	Mechanism	Notes
Minocycline	Microglial inhibitor (Toll-like receptor 4 blockade)	Oral antibiotic with CNS effects; studied in pain models
Ibudilast	Phosphodiesterase and glial modulator	Inhibits microglia/macrophage activation; oral agent
Propentofylline	Astrocyte/microglia inhibition	Experimental, used in animal models
Fluorocitrate	Inhibits astrocytic metabolism	Mainly used in research settings

 

2. Immune-Modulating Agents with Glial Activity

Agent	Notes
Low-dose naltrexone (LDN)	Reduces microglial activation via TLR4; being studied in chronic pain
Cannabinoids (CBD/THC)	Cannabinoid receptors on glia regulate inflammation; some clinical use
Palmitoylethanolamide (PEA)	Endogenous fatty acid amide; anti-inflammatory and glial modulator
Steroids	May suppress glial activation but have systemic immunosuppressive effects

 

3. Experimental Biologics and Peptides

Agent	Notes
Anti-TNF/IL-1 agents	Suppress cytokines released by activated glia
Fractalkine inhibitors	Block neuron-microglia signaling
P2X7 inhibitors	Target purinergic signaling in glia; experimental

 

Clinical Relevance to Endometriosis & Pelvic Pain

• Central Sensitization: Glial inhibitors are of particular interest in conditions where central sensitization amplifies pain, such as endometriosis, fibromyalgia, interstitial cystitis, and other visceral hypersensitivity syndromes.
• Mechanism: In these disorders, glial activation in the spinal cord and brainstem sustains and amplifies pain signals even after peripheral sources (e.g., lesions, inflammation) are removed.
• Evidence: Animal models and emerging clinical studies suggest that agents like minocycline, ibudilast, and LDN can reduce pain behaviors and glial activation, though robust human data are still limited.

Limitations

• Most glial inhibitors are experimental or used off-label in chronic pain management.
• Human clinical trials are limited but growing, especially for minocycline, ibudilast, and LDN.
• Long-term safety and efficacy remain under investigation.

APPENDIX 2 Key Features of Neuropeptidergic Circuits in Endometriosis

1. Neurotransmitters vs. Neuropeptides

• Neurotransmitters (e.g., serotonin, dopamine) are small, fast-acting molecules, typically mediating rapid, point-to-point synaptic transmission via ionotropic receptors.
• Neuropeptides (e.g., substance P, CGRP, VIP) are larger molecules, signaling more slowly and often through metabotropic, G-protein-coupled receptors. They can act over longer distances and timescales, modulating neuronal excitability and network function.

2. Common Neuropeptides in Pain and Sensory Circuits

Neuropeptide	Receptor	Main Functions
Substance P	NK1 receptor	Pain, inflammation, nausea, mood
CGRP	CGRP receptor	Migraine, vasodilation, neurogenic inflammation
VIP	VPAC receptors	Autonomic regulation, gut motility, circadian rhythm
NPY	Y receptors	Stress response, appetite, anxiety
Enkephalins/Dynorphins	Opioid receptors	Endogenous analgesia
Oxytocin/Vasopressin	OXTR/V1A	Social bonding, pain modulation, autonomic function

 

3. Circuit Characteristics

• Modulatory Role:
  Neuropeptides do not directly initiate action potentials but modulate the excitability and sensitivity of neurons, making nociceptors more or less responsive to stimuli.
• Volume Transmission:
  Unlike classic neurotransmitters, neuropeptides are often released outside of synaptic clefts and can diffuse to influence neighboring cells, effectively “broadcasting” signals across a wider area.
• Stress and Chronic Activation:
  Chronic stress, inflammation, or injury can dysregulate neuropeptidergic signaling, leading to persistent central sensitization and amplification of pain and nausea signals.

4. Clinical and Experimental Relevance in Endometriosis

Pain

• Substance P and CGRP are released from peripheral nociceptors and central terminals in the dorsal horn, promoting inflammation and pain amplification.
• Nav1.7 sodium channel activity can increase substance P release, highlighting interplay between ion channels and neuropeptides in pain circuits.

Nausea

• Substance P acts on NK1 receptors in the area postrema and nucleus tractus solitarius (NTS), key centers for nausea and vomiting.
• NK1 antagonists (e.g., aprepitant) block this pathway and are used clinically for severe nausea.

Migraine and Visceral Pain

• CGRP and substance P act in the trigeminovascular system, mediating migraine pain and vasodilation.
• Both CGRP inhibitors and Nav1.7 blockers (e.g., suzetrigine) are being explored for migraine and visceral pain management.

Central Sensitization & Chronic Syndromes

• Sustained neuropeptide release leads to glial activation, spinal cord wind-up, and altered limbic processing, resulting in multi-system amplification of pain, gastrointestinal dysmotility, nausea, and anxiety.
• In endometriosis, fibromyalgia, interstitial cystitis, and IBS, upregulated neuropeptidergic signaling is observed, with elevated substance P and CGRP in CSF and tissue, altered autonomic tone, and pain sensitization not fully explained by lesion burden alone.

5. Therapeutic Implications

• The recognition of neuropeptidergic circuits as central to endometriosis pain and neurovegetative symptoms underlies the rationale for therapies targeting:
  • Ion channels: Nav1.7, TRPV1
  • Neuropeptide receptors: NK1 (substance P), CGRP
  • Neuroinflammation: Glial inhibitors (e.g., minocycline, ibudilast, LDN)
• These approaches are especially valuable in patients with refractory symptoms where traditional hormonal or anti-inflammatory treatments are insufficient.

Summary:
Neuropeptidergic circuits—characterized by modulatory, long-range, and stress-responsive signaling—play a pivotal role in the pathophysiology of endometriosis. Their dysregulation contributes to both somatic and neurovegetative symptoms, providing a mechanistic foundation for novel, targeted therapies beyond hormonal modulatio

 References:

1. Yan et al. (2019). Neuropeptides Substance P and Calcitonin Gene Related Peptide Accelerate the Development and Fibrogenesis of Endometriosis. Scientific Reports, 9, 2698. (Demonstrated that sensory nerve peptides SP and CGRP promote EMT, myofibroblast transformation, and fibrosis in endometriotic lesions via NK1R and CGRP-receptor pathways; blocking these receptors reduced lesion fibrogenesis)nature.comnature.com.
2. Hao et al. (2021). Reduced vagal tone in women with endometriosis and auricular vagus nerve stimulation as a potential therapeutic approach. Scientific Reports, 11, 1345. (Showed endometriosis patients have lower vagus nerve activity; in a mouse model, vagus nerve stimulation shrank lesions and alleviated pain, indicating parasympathetic anti-inflammatory effects. Also provides background on SP and CGRP causing vasodilation and histamine-mediated inflammation in lesions)nature.comnature.com.
3. Liang et al. (2018). Villainous role of estrogen in macrophage-nerve interaction in endometriosis. Reprod. Biol. Endocrinol., 16, 122. (A review highlighting that estrogen amplifies cross-talk between nerves and macrophages in endometriosis; macrophages secrete NGF and cytokines under estrogen drive, which chronically stimulate peripheral nerves and contribute to neuropathic pain in endo) rbej.biomedcentral.com
4. The EDS Clinic (2023). The Role of Mast Cells in Endometriosis. (An educational article discussing how mast cells in endometriosis release inflammatory mediators and interact with nerves. Describes the feedback loop wherein sensory nerves release substance P activating mast cells, and mast cell mediators in turn exacerbate nerve pain)eds.cliniceds.clinic.
5. Sangiuliano et al. (2022). Non-hormonal therapies for endometriosis-associated pain: a systematic review. Gynecologic Endocrinology, 38(10): 883-888. (Summarized in EndoNews: found that dopamine agonists and the JNK inhibitor bentamapimod showed positive results in RCTs for pain reduction; anti-TNF agents and statins did not prove effective)endonews.comendonews.com.
6. Muñoz & Coveñas (2020). The Neurokinin-1 Receptor Antagonist Aprepitant: An Intelligent Bullet against Cancer? Cancers (Basel), 12(9): 2682. (Review of NK-1 receptor antagonists; notes that NK-1 blockers like aprepitant have broad pharmacological actions, including anti-inflammatory and analgesic effects, beyond their antiemetic use)mdpi.com.